FindTrial
Sign In

Eribulin mesylate injection

DRUG4 trials

Sponsors

Gilead Sciences, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Advanced MalignanciesBreast CancerFludzoparib" and Anti-angiogenicHRD-positive/HER2-negative Advanced Breast CancerMetastatic Breast CancerRecurrent Breast Cancer

Phase 1

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
RecruitingNCT06202261
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignancies, Metastatic Breast Cancer, Recurrent Breast Cancer
Start: 2023-04-13End: 2027-10-31Target: 154Updated: 2024-03-12

Phase 3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Active, not recruitingNCT04639986
Gilead SciencesMetastatic Breast Cancer
Start: 2020-11-23End: 2026-12-01Updated: 2026-02-09
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
RecruitingNCT06079983
Jiangsu Alphamab Biopharmaceuticals Co., LtdBreast Cancer
Start: 2023-12-01End: 2029-03-01Target: 400Updated: 2025-09-12
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
RecruitingNCT06255392
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
Start: 2024-06-12End: 2031-03-31Target: 200Updated: 2025-08-15

Related Papers

Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.
Journal of Clinical Oncology2025-05-28
Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.
2024-10-0125 citations
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.
Journal of Clinical Oncology2024-06-013 citations
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.
2024-04-0517 citations